For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$271.77
Thesis
Alnylam is the RNA-interference (RNAi) platform leader, having turned a Nobel-winning mechanism into a commercial franchise of approved silencing therapeutics. AMVUTTRA's expansion into ATTR cardiomyopathy moves the company from rare-disease revenue into a large cardiovascular market, the inflection that underwrites sustained profitability.
The investment case is a durable, reusable platform — one delivery-and-chemistry stack applied across many indications — now reaching commercial scale and self-funding its pipeline. Risks: competition in the TTR market (Pfizer's tafamidis, BridgeBio, Ionis), pricing pressure, and the usual clinical risk on next-wave cardiometabolic programs.
Catalysts
- AMVUTTRA ATTR-cardiomyopathy launch trajectory
- TTR-market competitive dynamics
- Cardiometabolic pipeline readouts (e.g. subcutaneous programs)
- Margin inflection as the commercial base scales